PurposeTo compare the academic achievement obtained in Neurosurgery in a class of undergraduate students according to the pedagogical methodology employed: flipped classroom (FC) versus traditional lecture. Students' satisfaction with the FC model is also analyzed.MethodsA quasi-experimental study was designed. The traditional lecture was the pedagogical method employed in teaching units (TUs) 1, 2, and 3 (61, 60, and 66 enrolled students, respectively), whereas TU 4 (69 enrolled students) used the FC methodology.ResultsThe dropout rate was lower, whereas the academic achievement and the rate of correct answers were higher in TU 4 compared to the rest of the TUs, but these results were not statistically significant. However, the mean score obtained in Neurosurgery was significantly higher in TU 4 compared to the rest of the TUs (p = 0.042). Active learning activities based on clinical cases were positively emphasized. The main weakness was with the time consumed for video-recorded lecture viewing.ConclusionsThe FC approach showed better academic results than traditional lectures when comparing students in the same Medical School during the same academic year undergoing the same exam. The students rated the FC approach positively, considering it stimulating and useful for learning.

Background Osteoporotic vertebral compression fracture (VCF) is the third most frequent fragility fracture in the world. Conservative treatment, vertebroplasty, and kyphoplasty are all recognized therapies. However, diagnostic and therapeutic recommendations must be more consistent when comparing clinical guidelines. This study aims to compare the efficacy of vertebral augmentation therapy and conservative management for treating VCFs, the risk of subsequent complications, and the length of hospital stay. Method All patients over 50 years old with a diagnosis of thoracic or lumbar VCF without underlying oncological process, treated conservatively or surgically, and consecutively attended at our department from January 2017 to June 2021 were retrospectively selected for analysis. Patients who missed follow-up or died during the first three months were excluded. Results A total of 573 cases were selected for analysis. Most patients were treated conservatively (85.3%). Both groups were homogenous regarding epidemiological and clinical features. The median time elapsed to achieve pain relief was significantly lower in the surgical cohort (4.5 vs. 10 weeks, p < 0.001), and the proportion of patients reporting pain at the first outpatient visit was also significantly lower with a vertebral augmentation procedure ( p = 0.004). The new fracture rate and the adjacent level rate did not differ significantly when comparing both treatments, whereas the progression of the diagnosed fracture was more frequent in the conservative group (4.8% vs. 29.7%; p < 0.001). The median hospital stay was significantly lower in the conservative group (3 vs. 10 days; p < 0.001). Conclusion Surgical treatment (vertebroplasty/kyphoplasty) of VCFs was associated with sooner pain relief without an increased risk of new or adjacent fractures. Moreover, the progression of treated fractures was significantly lower in the surgical cohort. The only unfavorable aspect was the more extended hospital stay compared with the conservative treatment group.

Purpose Neutropenia is a frequently observed complication in solid organ transplant recipients as a result of immunosuppressive therapy and antimicrobial prophylaxis. The impact of neutropenia on the outcome of lung transplant recipients remains understudied.Our main objective was to analyse the frequency of neutropenia in the first 18 months after surgery.As a secondary objective, we assessed the association between the treatment of neutropenia with granulocyte colony-stimulating factor (GCSF) and overall survival (OS), acute rejection (AR) and chronic lung allograft dysfunction (CLAD). Methods We reviewed the outcomes in the first 18 months after surgery of 305 lung transplant recipients performed between 2009 and 2019. Neutropenia was categorised as mild (N 1000-1500), moderate (<1000) and severe (<500). Association of the use of GCSF with OS, AR and CLAD was performed using a Cox model, logistic regression and a Fine-Gray model, respectively. Results More than half of the patients included in this review 51.8% (158/305) developed at least one episode of neutropenia. In 107 patients (35.06%) neutropenia persisted in more than one period of three months follow-up. Neutropenia was detected in 267 of the 1554 follow-up visits (17.18%). The severity of was categorised as mild in 134 cases (50.19%), moderate in 100 (37.45%) and severe in 33 (12.36%). Treatment with GCSF was indicated in 71 patients (23%) and the mean doses per patients was 3.53 units (SD ± 4.2). We did not observe an association between neutropenia and the development of AR, CLAD or overall survival. However, there was higher mortality in patients who received GCSF compared to those who did not (HR 2.30 95%CI 1.32; 4.00, p=0.003) (Figure 1). Conclusion Neutropenia is very common in lung transplant recipients and may be persistent in more than one third of cases. In our series, the need for treatment with GCSF has been a marker of poor prognosis.

Purpose The aim of this study is to identify risk factors for vertebral compression fracture (VCF) progression in patients treated conservatively with a brace. Then, a case–control study was designed. Methods All patients over 50 years old with diagnosis of thoracic or lumbar VCF (T5 to L5) in absence of underlying oncological process, treated conservatively with brace, and consecutively attended at our department from January 2017 to June 2021 were retrospectively selected for analysis. Patients missed for follow-up or dead during the first 3 months of follow-up were excluded. Results Five hundred and eighty-two consecutive patients were recorded. Incomplete follow-up excluded 74 patients and other 19 died in the first three months after diagnosis, so 489 cases were finally analyzed. Median follow-up was 21 (IQR 13;30) weeks. Increased collapse of the vertebral body was found in 29.9% of VCFs with a median time to progression of 9 (IQR 7;13) weeks. Male gender (OR 1.6), type A3 fracture of the AOSpine classification (OR 2.7), thoracolumbar junction location (OR 1.7), and incorrect use of the brace (OR 3.5) were identified as independent risk factors for progression after multivariable analysis. Conclusion Male gender, type A3 fracture of the AOSpine classification, thoracolumbar junction location, and incorrect use of the brace were identified as independent risk factors for VCF progression, which resulted in worse pain control, when treated with brace. Thus, other treatments such as percutaneous vertebral augmentation could be considered to avoid progression in selected cases, since collapse rate has been demonstrated lower with these procedures.

The advent of immune-checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC) has significantly improved the overall survival (OS) of these patients in comparison to chemotherapy (CTh). Currently, it is estimated that long-term survival can be achieved in more than 15% of patients treated with ICIs, being two years of treatment a cut-off point established by most clinical trials. However, in routine clinical practice, discontinuation of ICI therapy after two years is not yet universally accepted.

Introduction/Aim: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) is a heterogeneous and aggressive group with a high mortality rate, thus, to improve risk stratification in terms of survival, several studies have been performed with 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F] FDG PET/CT) to assess the total tumor burden, through volumetric parameters such as tumor metabolic volume (MTV) and total lesion glycolysis (TLG). The aim is to evaluate the relationship of MTV and TLG with progression-free survival (PFS) and overall survival (OS), and their correlation with prognostic factors Beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH). Methodology: Retrospective study of 44 patients with LBDCG undergoing baseline 2-[18F]FDG PET/CT between January 2012 and December 2018. The calculation method for VMT and TLG was the SUV2.5 threshold. For the evaluation of VMT and TLG with PFS and OS, Harrell's C-index was used, after performing a Cox proportional hazards regression model. Pearson's correlation coefficient was used to correlate VMT and TLG with B2M and LDH. Results: In relation to OS and PFS the VMT2.5 (p 0.006; p <0.001) showed statistically significant differences, while TLG2.5 (p 0.078; p <0.001) was statistically significant only in PFS. When comparing VMT2.5 and TLG2.5, VMT2.5 obtained a higher Harrell's C statistical concordance index for both OS (p 0.025) and PFS (p 0.008) showing great ability to discriminate between patients in whom the event does or does not occur. In the Pearson correlation analysis, VMT2.5 showed a good correlation with LDH (0.676) and a poor correlation with B2M (0.348). The TLG2.5 presented lower correlation with LDH (0.629) and poor correlation with B2M (0.274). Table 1. Univariate analysis to evaluate the discriminatory capacity of each variable for both OS and PFS. SG Volumetric Parameter Harrell's C p-value MTV 2.5 0.7407 0.025 TLG 2.5 0.6990 SLP Volumetric Parameter Harrell's C p-value MTV 2.5 0.8010 0.008 TLG 2.5 0.7595 Conclusion: The volumetric parameter MTV2.5 calculated with 2-[18F]FDG PET/CT can be a good prognostic indicator to predict PFS and OS in patients with DLBCL-NOS. In addition, it presents a good correlation with LDH.

OBJECTIVES:To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients.METHODS:Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous thromboembolic events (VTE) and evaluated the incidence and the attributed risk of each CRF.RESULTS:5424 admissions in patients diagnosed with APS were identified. 64.6% were women and the mean age was 54.6. The mortality rate was 3.1%. Overall, 35.8% of patients had hypertension, 14% were diabetic, 21.7% hypercholesterolaemic, 9.9% obese and 26.7% smokers. Thromboembolic events (67.9% arterial and 32.1% venous) accounted for 11.9% of admissions and 7.1% of deaths. Male sex (OR 1.83, 95% CI 1.41-2.21), cholesterol (OR 1.25, 95% CI 1.01-1.54) and smoking (OR 1.49, 95% CI 1.22-1.81) were independently associated with thromboembolic events. Meanwhile, patients with ATE were older (57 vs. 54.1 years p=0.033), and presented more secondary APS (17.1% vs. 10.6%, p=0.034), hypertension (47.7% vs. 33.5%, p=0.001), diabetes (16.9% vs. 9.6%, p=0.017), cholesterol (34.3% vs. 17.8%, p<0.001) and smoking habit (41.2% vs. 24%, p<0.001) when compared with VTE. Risk factors independently associated with ATE events were male sex (OR=1.61, 95% CI=1.30-2.03), hypertension (OR=1.30, 95% CI=1.03-1.64), cholesterol (OR=1.51, 95% CI=1.18-1.94) and smoking habit (OR=1.84, 95% CI=1.47-2.32), while VTE events were determined by male sex (OR=2.06, 95% CI=1.53-2.77) and obesity (OR=1.61, CI=1.02-2.52).CONCLUSIONS:Thromboembolic events in APS were in part determined by a high prevalence of CRF. The identification of distinct profiles may allow us to undertake a more personalised approach to reduce thromboembolic events and to individualise anticoagulant and antiplatelet therapy.

Breast cancer (BC) is the most common cause of cancer-related death in young women, but stages I to III are highly curable regardless of age. Classically HER2-positive disease has been considered a poor prognosis but few studies have evaluated the impact of anti-HER2 treatments. Knowing the risk of recurrence and time to recurrence can determine follow-up and time to follow, key issues for a population with a potentially long survival. A retrospective analysis of YBCP (≤45 years) treated at HUPHM, diagnosed with early infiltrating breast cancer between 2009-2019 and with a mínimum follow up of 24 months was made. We analyzed distant disease-free survival (DDFS) and time to distant relapse adjusted by subtypes and stage in patients with stages I to III. The Kaplan-Meier method, Kruskall-Wallis technique and Mann Whitney test were carried out to analyze DDFS and the interaction between prognostic variables. 519 patients were included, triple negative (TN) 12.3%; HHRR+/HER2- 71.1%; HHRR+/HER2+ 12.1%; HHRR-/HER2+ 4.5%. With a median follow-up of 70.4 months, 16% of relapses were observed. A significant association between histological subtype and DDFS was presented P=0.0024, median DDFS or death of 22.7, 61.3, 60.7, y 68.6 months for TN, HHRR+/HER2-, HHRR+/HER2+ and HHRR-/HER2+ respectively. We detected a significantly shorter time to recurrence or death for TN breast cancer, P=0.003. No differences were founded between HHRR-positive disease and HHRR-negative/HER2-positive in time to distant relapse. Early breast carcinoma is highly curable also in YBCP but follow up is needed due to the risk of recurrence. Triple-positive disease seems to be the best prognostic subtype. The type of follow up and its duration are not universally established, and can be adapted to the risk of each patient. We observed an association between tumor subtype and the time of distant recurrence, with the shorter systemic recurrence time for TN patients. For the rest of subtypes, we did not observe any difference between them. Our real-life data also reflect a prolonged DDFS for patients with HHRR+ or HER2+, close to 5 years even for stage III, changing the classical prognosis described for HER2-positive disease, suggesting the need for prolonged follow up.

Lung cancer (LC) patients are a risk population for Emergency Department (ED) consultation, but information on unplanned care patterns is limited. Optimizing outpatient care requires understanding the acute care needs of our patients.

Breast cancer (BC) remains the most common malignancy among young female patients and the leading cause of cancer death in this population. BC in young women is a social problem since it often appears during the period of highest family and professional activity. Very often, YBCP are classified as high risk only by age. A retrospective analysis of women with BC diagnosed between 2009-2019 in HUPHM in Madrid and ≤ 45 years old at the moment the diagnosis was made. Survival was analyzed according to histopathological subtypes and stages in this population. The Cox proportional hazards model could not be used because our variables could not meet the proportional hazards (PH) assumption. Instead, the RMST at 60 months has been analyzed as an alternative, which means expected survival time subject to a specific time horizon. Kaplan Meier curves were also estimated. A total of 537 YBCP were analyzed, 104 events were defined (relapse) with a median follow up of 69 months. The patients were divided by histopathological subtypes and stages, and no significant differences were found between stages according to histological subtypes. RMST was clearly diminished independently stage in triple negative and HR-/HER2+ disease (except for stage III due to a low number of subjects). These differences were greater within stage III between triple-negative disease and the other histologies. These results were compared with a Kaplan Meier analysis at 24 and 60 months showing that the risk of relapse was higher in the HR-negative subtypes regardless of HER2 status.Table: 149PTNRH+/HER2-RH+/HER2+RH-/HER2+n603575821Stage (S): n (%)p=.03I12 (20%)144 (40%)15 (26%)7 (33%)II33 (55%)141 (39%)25 (43%)10 (47%)III15 (25%)72 (20%)18 (31%)4 (19%)Relapses: n (%)14 (23%)52 (15%)7 (12%)6 (27%)RMST Expected average survival time within 60 monthsS I: Average time (AT) (95%IC)50,5 (40-61)59 (58-60)60 (60-60)52,6 (39-66)S II: AT (95%IC)51,5 (45-57)57,3 (55-59)60 (60-60)55,3 (49-61)S III: AT (95%IC)42,3 (30-55)51,7 (48,1-55)54,3 (48-60)56,6 (51-62)Relapse Free Survival Rate at 24 // 60 monthsS I91%/61,1 %99%/94%100%/100%83,3%/83%S II93%/73,9%97%/87,5%100%/100%100%/75%S III69%/56%91%/72%94%/ 79,3%100%/66%All stages87%/67%96%/86%97,9%/92%90%/73% Open table in a new tab The RMST is a valid tool to analyze the risk of relapse according to the tumor biology and the stage at the time of diagnosis, being comparable to the PH in detecting differences between arms when hazards are proportional, but better when they are not.

BackgroundImmunotherapy (IO) represents one of the most promising therapeutic approaches in systemic cancer treatment. However, its broad clinical application revealed several important cardiovascular side effects which can limit treatment options, decrease patients' prognosis and quality of life. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) and the incidence of cardiovascular events (CVE) in patients treated with IO. This has been little researched, and the information we have is scarce.MethodsWe conducted a retrospective study in a single institution including oncological patients treated with IO from 2014 to 2020. We analyzed their CVRF and the CVE developed during IO treatment.ResultsTable: 78PSexMale 64.5%Female 35.5%Median age61.0Hypertension40.7%Diabetes13.2%Hypercholesterolemia30.4%Smoking habit81.2%Coronary syndrome5.0%Congestive heart failure0.5%Chronic renal failure4.5%Arrythmia6.4%Peripheral arterial disease17.2%Type of tumorLung cancer 62.4%Melanoma 12.7%Renal cell carcinoma 5.0%Bladder cancer 4.8%Head and neck tumors 4.2%Hepatocellular carcinoma 2.4%Lymphoma 2.1%Gastrointestinal tumors 3.2 %Gynecological tumors 0.8%Breast cancer 0.8%Thymoma 0.5%Previous cardiotoxic treatmentsAnthracyclines: 3.4%Cisplatin: 23.0%Antiangiogenic therapy: 13.0%HER2 targeted therapy: 0.5%Thoracic radiotherapy: 25.1% Open table in a new tab ConclusionsAlmost one fifth of the patients in our study experienced some kind of CVE but its association with IO remains unclear, as only 1% of the events were clearly related to IO. Prospective studies with cardiovascular comprehensive follow-up protocols are needed to assess if there is a real casuistic relationship between the cardiac events in this population and IO treatment.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. BackgroundImmunotherapy (IO) represents one of the most promising therapeutic approaches in systemic cancer treatment. However, its broad clinical application revealed several important cardiovascular side effects which can limit treatment options, decrease patients' prognosis and quality of life. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) and the incidence of cardiovascular events (CVE) in patients treated with IO. This has been little researched, and the information we have is scarce. Immunotherapy (IO) represents one of the most promising therapeutic approaches in systemic cancer treatment. However, its broad clinical application revealed several important cardiovascular side effects which can limit treatment options, decrease patients' prognosis and quality of life. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) and the incidence of cardiovascular events (CVE) in patients treated with IO. This has been little researched, and the information we have is scarce. MethodsWe conducted a retrospective study in a single institution including oncological patients treated with IO from 2014 to 2020. We analyzed their CVRF and the CVE developed during IO treatment. We conducted a retrospective study in a single institution including oncological patients treated with IO from 2014 to 2020. We analyzed their CVRF and the CVE developed during IO treatment. ResultsTable: 78PSexMale 64.5%Female 35.5%Median age61.0Hypertension40.7%Diabetes13.2%Hypercholesterolemia30.4%Smoking habit81.2%Coronary syndrome5.0%Congestive heart failure0.5%Chronic renal failure4.5%Arrythmia6.4%Peripheral arterial disease17.2%Type of tumorLung cancer 62.4%Melanoma 12.7%Renal cell carcinoma 5.0%Bladder cancer 4.8%Head and neck tumors 4.2%Hepatocellular carcinoma 2.4%Lymphoma 2.1%Gastrointestinal tumors 3.2 %Gynecological tumors 0.8%Breast cancer 0.8%Thymoma 0.5%Previous cardiotoxic treatmentsAnthracyclines: 3.4%Cisplatin: 23.0%Antiangiogenic therapy: 13.0%HER2 targeted therapy: 0.5%Thoracic radiotherapy: 25.1% Open table in a new tab ConclusionsAlmost one fifth of the patients in our study experienced some kind of CVE but its association with IO remains unclear, as only 1% of the events were clearly related to IO. Prospective studies with cardiovascular comprehensive follow-up protocols are needed to assess if there is a real casuistic relationship between the cardiac events in this population and IO treatment. Almost one fifth of the patients in our study experienced some kind of CVE but its association with IO remains unclear, as only 1% of the events were clearly related to IO. Prospective studies with cardiovascular comprehensive follow-up protocols are needed to assess if there is a real casuistic relationship between the cardiac events in this population and IO treatment.

There are currently no predictive biomarkers for long-term survival after neoadjuvant chemoimmunotherapy. However, the identification of non-small lung cancer (NSCLC) patients who obtain long-term benefit from chemoimmunotherapy is essential to optimize therapies.

Overfitting is a common problem in the development of predictive models. It leads to an optimistic estimation of apparent model performance. Internal validation using bootstrapping techniques allows one to quantify the optimism of a predictive model and provide a more realistic estimate of its performance measures. Our objective is to build an easy-to-use command, bsvalidation, aimed to perform a bootstrap internal validation of a logistic regression model.

Neoadjuvant chemoimmunotherapy been shown to be highly effective in resectable stage IIIA NSCLC. Now we provide long term survival data This was an open-label, multicentre, single-arm phase 2 trial in which patients with histologically or cytologically documented stage IIIA NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 and who were deemed locally to be surgically resectable by a multidisciplinary clinical team were treated with neoadjuvant intravenous paclitaxel (200 mg/m2) and carboplatin (area under curve 6; 6 mg/mL per min) plus nivolumab (360 mg) on day 1 of each 21-day cycle, for three cycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 months, followed by 480 mg every 4 weeks for 8 months). Here we report progression-free survival (PFS) and Overall survival (OS) at 36 and 42 months, assessed in the modified intention-to-treat population (ITT), which included all patients who received neoadjuvant treatment, and in the per-protocol population (PP), which included all patients who had tumour resection and received at least one cycle of adjuvant treatment. Median follow-up time was 37.9 months (95%CI: 36.7-40.7), with a 94% maturity at 36 months. Among the ITT population (N=46), 37 patients, constituting the PP population, received subsequent adjuvant therapy. Of them, 27 (58.7%) patients completed the adjuvant treatment (16 cycles), 10 (21.7%) patients received between 3 and 15 cycles of adjuvant therapy, and 9 (19.6%) patients did not receive adjuvant therapy. At the time of data cutoff (March 2021), progression disease was diagnosed in 14 patients and 9 deaths were recorded in the ITT population. Of these, three deaths corresponded to patients who did not undergo surgery and had disease progression, four deaths corresponded to patients who underwent surgery and had disease progression, and the two remaining deaths corresponded to patients who were diagnosed as being disease free but died from COVID19 infection. Notably, among patients who could not undergo surgery (N=5), one of them is still alive and with no evidence of disease. PFS at 36 and 42 months in the ITT population were 69.6% (95%CI: 54.1-80.7), in both cases. Similarly, PFS at 36 and 42 in the PP population were 81.1% (95%CI: 64.4-90.5) in both cases. The percentage of patients who were alive at 36 and 42 months in the modified ITT population were 81.86% (95% CI: 66.8-90.6) and 78.94% (95%CI: 63.1-88.6), respectively. Likewise, OS at 36 and 42 months in the PP population was 91.0% (95%CI: 74.2-97.0) and 87.3% (95%CI: 69.3-95.1), respectively. The efficacy of nivolumab in combination with platinum-based chemotherapy in patients with resectable stage IIIA NSCLC is clearly supported by long term survival data.

espanolIntroduccion y objetivos El volumen metabolico tumoral (VMT) es un indicador de pronostico prometedor en el linfoma B difuso de celulas grandes (LBDCG). El objetivo del presente estudio es evaluar los diferentes metodos para el calculo del VMT basal con la tomografia por emision de positrones/tomografia computarizada con 18F-fluorodesoxiglucosa (18F-FDG PET/TC) en pacientes con LBDCG, relacionando cada uno de los volumenes medidos con la supervivencia libre de progresion (SLP) y la supervivencia global (SG). Metodologia Se trata de un estudio de cohortes retrospectivo analitico, en el que se incluyeron 34 pacientes sometidos a un 18F-FDG PET/TC basal previo al tratamiento. Comparamos tres umbrales SUV 2,5, SUV 40% del SUV maximo y SUV medio hepatico (PERCIST), para el calculo de los biomarcadores VMT y glucolisis total de la lesion (TLG) relacionandolos con la SLP y SG. El mejor modelo predictivo se selecciono en funcion del valor de criterio de informacion de Akaike (AIC) despues de realizar una regresion de riesgos proporcionales de Cox. Resultados Con relacion a la SLP, muestran diferencias estadisticamente significativas: VMT 2,5, TLG 2,5, VMT 40%, TLG 40%, VMT y TLG calculados con el umbral PERCIST. Entre estos, el que tiene un AIC menor es VMT 2,5, por lo que se considera el mejor parametro para predecir la SLP. Con respecto a la SG, muestra diferencias estadisticamente significativas: VMT 2,5, VMT y TLG calculados con el umbral PERCIST. Entre estos tres, el que tiene un AIC menor es VMT 2,5, por lo que se considera el mejor parametro para predecir la SG. Ademas, un mayor valor de VMT y TLG, se asocia a peor SLP y SG Conclusion El VMT calculado con el umbral SUV 2,5 parece ser el mejor parametro para predecir la SLP y SG en los pacientes diagnosticados con LBDCG con el 18F-FDG PET/TC. EnglishIntroduction and objectives Metabolic tumor volume (MTV) is a promising indicator of prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of the present study is to evaluate the different methods for the calculation of the basal metabolic tumor volume with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in the patients with DLBCL, relating each one of the volumes measured with progression-free survival (PFS) and overall survival (OS). Methodology This is a retrospective analytical cohort study, in which 34 patients underwent to 18F-FDG PET/CT baseline prior to treatment. We compared three SUV thresholds 2.5, SUV 40% of the maximum SUV and SUV mean hepatic uptake (PERCIST) for the calculation of MTV and total lesion glycolysis (TLG) biomarkers, relating them to the PFS and OS. The best predictive model was selected based on the Akaike‘s information criterion (AIC) after performing a Cox proportional hazards regression. Results In relation to the PFS, they show statistically significant differences: MTV 2.5, TLG 2.5, MTV 40, TLG 40, MTV and TLG calculated with the PERCIST threshold. Among these, the one that has a lower AIC is MTV 2.5, so it is considered the best parameter to predict the PFS. With respect to OS, it shows statistically significant differences: MTV 2.5, VMT and TLG calculated with the PERCIST threshold. Among these three, the one with the lowest AIC is MTV 2.5, which is why it is considered the best parameter to predict OS. In addition, a higher value of MTV and total tumor glycolysis (TLG), is associated with worse PFS and OS Conclusion The MTV calculated with the threshold SUV 2.5 seems to be the best parameter to predict PFS and OS in patients diagnosed with DLBCL with 18F-FDG PET/CT.